REGENXBIO announces second pivotal trial, ASCENT, in RGX-314 clinical program
January 18th 2022ASCENT, REGENXBIO’s Phase III clinical trial conducted in partnership with AbbVie, is expected to enroll patients in the United States and Canada, with pivotal trials expected to support BLA submission for RGX-314 in 2024.
Read More
Eye care industry takes action on World Sight Day to preserve vision worldwide
October 14th 2021Today marks World Sight Day, an annual day of awareness intended to focus global attention on blindness and vision impairment. Coordinated by the International Agency for the Prevention of Blindness, this year’s call is for everyone to “Love Your Eyes.”
Read More
Dissecting real-world registry study of YUTIQ for chronic non-infectious posterior uveitis
October 12th 2021Ankur Shah, MD, discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.
Read More